MYOS Reports Positive Results From Fortetropin(R) Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MYOS Reports Positive Results From Fortetropin(R) Clinical Study

CEDAR KNOLLS, NJ--(Marketwired - Apr 22, 2016) - MYOS RENS Technology Inc. ("MYOS" or the "Company") ( NASDAQ : MYOS ), an emerging  biotherapeutics and  bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the positive results of a recent clinical study which demonstrated that the daily use of 4 grams of Fortetropin, which is approximately 40% lower than the currently-recommended 6.6 grams dose, results in statistically significant decreases in serum myostatin levels. A plethora of evidence has linked decreases in serum myostatin levels with gains in lean muscle mass.

"We expect the positive results of this important clinical study to contribute to the success of our aggressive commercialization strategy for Fortetropin®," said Robert J. Hariri, M.D., Ph.D., Chairman of MYOS. Dr. Hariri continued, "at a dose as low as 4 grams per day in the broad population, along with exercise, Fortetropin may be beneficial for improving lean muscle mass, which has significant therapeutic benefits for overall health including bone density, control of serum glucose, triglyceride levels and reducing inflammation." The Company's abstract, entitled "A Dose-Ranging Study of the Natural Myostatin Reducing Agent, Fortetropin®, in Young Adult Males and Females" will be presented at the International Conference on Frailty & Sarcopenia Research to be held April 28-29, 2016 in Philadelphia. The clinical study, which was led by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory at The University of Tampa, examined the effects of Fortetropin supplementation on serum myostatin levels at various dosing levels in young adult males and females. The purpose of this study was to enable MYOS to better define the dose response curve for Fortetropin, the minimal effective dose of Fortetropin and the effects of Fortetropin on serum myostatin. Co-authors of the clinical study from MYOS included Maghsoud Dariani, M.S., Head of Science & Technology, and Neerav D. Padliya, Ph.D., Vice President, Research Alliances.

About Fortetropin® Fortetropin® is a natural, myostatin reducing agent that is derived from fertilized chicken egg yolk using patented proprietary technology. Myostatin is a natural regulatory protein that inhibits the growth of new muscle tissue, and thus plays a central role in skeletal muscle health. In a double-blind, placebo-controlled trial conducted in 2014 at The University of Tampa to evaluate the effects of Fortetropin, Dr. Wilson observed a statistically significant decrease in serum myostatin levels in addition to an increase in muscle size and lean body mass in average males over a 12 week period while performing modest resistance training. Dr. Wilson commented, "The data from our 2014 study clearly demonstrated that Fortetropin resulted in statistically significant muscle gains in recreationally-trained individuals at the recommended dose of 6.6 grams per day. Males taking daily supplements of Fortetropin and exercising twice a week showed impressive gains in muscle growth and lean body mass, which are both key components for overall health and longevity."

About MYOS RENS Technology, Inc. MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin reducing agent. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myosrens.com .

Forward-Looking Statements Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, market acceptance of our existing and future products in countries outside of the United States (such as Canada and China), the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to increase shareholder value, the ability to generate revenue and cash flow from sales of Fortetropin® and Rē Muscle Health™ products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Company Contact MYOS RENS Technology Inc. Joseph DosSantos Chief Financial Officer MYOS RENS Technology Inc. (973) 509-0444 Email Contact Investor Relations Contact Michael Briola CEO Motion Communications, Inc. Email Contact (972) 646-3400

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 99

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 152

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 66

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Universal Haptics Protocol May Cut Integration Friction

Updated Category News Views 245

A controller rumbling at the wrong moment is a small annoyance, but the plumbing behind that rumble has been a stubborn mess for years. The Haptics Industry Forum's Universal Haptics Protocol 1.0, announced November 17, 2026, is an attempt to clean up that mess with a shared language between software and touch-feedback hardware. This is not the sort of release that sends...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 95

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 44

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 154

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 130

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading

Top 5 Most Recently Viewed Articles

Chanel Georges Shines Bright as Staffing Industry Leader

Updated Category News Views 154

Chanel Georges Recognized as a Leader in Staffing In an exciting development within the staffing industry, Chanel Georges, the Executive Vice President at Host Healthcare, has been celebrated for her remarkable achievements. She has been included in the prestigious SIA’s Global Power 150 Women in Staffing list, honoring women whose contributions make a significant...

Continue Reading
Omni Workspace Appoints Jessica Volkenant as Sales VP

Updated Category News Views 177

Omni Workspace Welcomes New Regional VP of Sales Omni Workspace is excited to announce the appointment of Jessica Volkenant as the Regional Vice President of Sales for its Minneapolis location at Atmosphere Commercial Interiors. This strategic appointment is aimed at enhancing sales capabilities and client relationships across the region. What This Means for Atmosphere...

Continue Reading
Xizang's Transformation: 75 Years of Economic Progress

Updated Category News Views 158

Astonishing Growth: Xizang's Economic Leap Bluntly speaking, Xizang has undergone an absolute metamorphosis since its liberation 75 years ago. I mean, we're talking about GDP numbers that jumped from a paltry 327 million yuan to a whopping 303.2 billion yuan. If that doesn't get your investor juices flowing, nothing will. It's a clear testament to the seismic shifts that...

Continue Reading
Hub Group Settles Securities Claims: Legal Insight

Updated Category News Views 23

Under the Microscope: Hub Group Faces the Music Oh boy, Hub Group's got a heap of trouble on its hands and, frankly, it isn't an isolated incident in this wild market game. When it comes to brass-tacks, the company's fraudulent song and dance routine, according to allegations, managed to stretch from April 28, 2023, to May 11, 2026. That's three years of potential...

Continue Reading
Europe's Mining Equipment Market Set for Significant Growth

Updated Category News Views 162

Future of Underground Mining Equipment in Europe The Europe underground mining equipment market is gearing up for remarkable growth, with projections indicating an increase from USD 6.4 billion in the ongoing year to an estimated USD 8.9 billion by the end of the next decade. This trajectory represents a compound annual growth rate (CAGR) of approximately 3.72%. The...

Continue Reading